L. Chelis

发表

Prognostic role of APC and RASSF1A promoter methylation status in cell free circulating DNA of operable gastric cancer patients.

E. Chatzaki, E. Lianidou, I. Balgkouranidou, 2015, Mutation research.

Methylation status of the APC and RASSF1A promoter in cell-free circulating DNA and its prognostic role in patients with colorectal cancer.

E. Lianidou, K. Romanidis, I. Balgkouranidou, 2016, Oncology letters.

Prognostic significance of different immunohistochemical S100A2 protein expression patterns in patients with operable nonsmall cell lung carcinoma

P. Karakitsos, I. Panayiotides, P. Foukas, 2012, OncoTargets and therapy.

Etoposide plus cisplatin followed by concurrent chemo-radiotherapy and irinotecan plus cisplatin for patients with limited-stage small cell lung cancer: A multicenter phase II study.

V. Georgoulias, A. Kalykaki, A. Polyzos, 2010, Lung cancer.

Docetaxel plus gemcitabine in combination with capecitabine as treatment for inoperable pancreatic cancer: a phase II study

S. Kakolyris, N. Xenidis, L. Chelis, 2012, Cancer Chemotherapy and Pharmacology.

Transtympanic Injections of N-acetylcysteine for the Prevention of Cisplatin-induced Ototoxicity: A Feasible Method With Promising Efficacy

S. Kakolyris, N. Xenidis, L. Chelis, 2013, American journal of clinical oncology.

Complete response after sorafenib therapy for hepatocellular carcinoma in an HIV-HBV co infected patient: Possible synergy with HAART ? A case report

S. Kakolyris, N. Xenidis, V. Souftas, 2011, Medical oncology.

Hepatoid Adenocarcinoma of the Gallbladder

C. Simopoulos, A. Giatromanolaki, E. Sivridis, 2012, Journal of Gastrointestinal Cancer.

Docetaxel plus Oxaliplatin in Combination with Capecitabine as First-Line Treatment for Advanced Gastric Cancer

S. Kakolyris, N. Xenidis, A. Karayiannakis, 2011, Oncology.

Reversible Posterior Leukoencephalopathy Syndrome Induced by Pazopanib

S. Kakolyris, N. Xenidis, V. Souftas, 2012, BMC Cancer.

Salvage treatment with irinotecan/cisplatin versus pemetrexed/cisplatin in patients with non-small cell lung cancer pre-treated with a non-platinum-based regimen in the first-line setting: a randomized phase II study of the Hellenic Oncology Research Group (HORG)

V. Georgoulias, P. Economopoulou, A. Polyzos, 2017, Clinical and Translational Oncology.

Systematic review on T3 laryngeal squamous cell carcinoma; still far from a consensus on the optimal organ preserving treatment.

D. Pantazis, L. Chelis, M. Riga, 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Biweekly Vinorelbine and Gemcitabine as Second-Line Treatment and Beyond in Non-Small Cell Lung Cancer

E. Chatzaki, P. Karakitsos, S. Kakolyris, 2010, Chemotherapy.

Docetaxel plus cisplatin and bevacizumab for untreated patients with advanced/metastatic non-squamous non-small-cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group

S. Agelaki, V. Georgoulias, A. Soultati, 2013, Cancer Chemotherapy and Pharmacology.

A dose escalation study of docetaxel plus capecitabine in combination with oxaliplatin in patients with advanced solid tumors

E. Chatzaki, P. Karakitsos, S. Kakolyris, 2010, Acta oncologica.

Detection of Hepatocellular Carcinoma in a High-Risk Population by a Mass Spectrometry-Based Test

D. Mahalingam, K. Attwood, R. Iyer, 2021, Cancers.

Synchronous Breast and Rectal Cancers in a Man

C. Simopoulos, C. Tsalikidis, S. Kakolyris, 2011, Case Reports in Oncology.